Summary
Caladrius Biosciences Inc (Caladrius), formerly NeoStem, Inc., develops and manufactures cell therapy products. Its products are based on its proprietary technologies, Dendritic Cell-Tumor Cell technology; CD34 technology; and T Regulatory technology, for immuno-oncology, ischemic repair and immunomodulation. The company’s developmental pipeline products include CLBS20 (NBS20) for the treatment of metastatic melanoma, CLBS10 (formerly NBS10) for ST-elevation myocardial infarction and CLBS03 for type 1 diabetes. It offers services such as product and process development, engineering and automation, GMP manufacturing, cell and tissue processing, storage and distribution, and expert consulting and regulatory support. The company offers products and services to biotechnology, pharmaceutical and medical product companies, and leading academic research institutions. Caladrius is headquartered in Basking Ridge, New Jersey, the US.
Caladrius Biosciences Inc (CLBS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Caladrius Biosciences Inc, Medical Devices Deals, 2011 to YTD 2017 11
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Amorcyte Raises US$0.5 Million In Venture Financing 14
Partnerships 14
Kiadis Pharma Enters into Agreement with PCT 14
Caladrius Biosciences Enters into Development Agreement with Sanford Research 15
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 16
NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 17
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 18
Licensing Agreements 19
Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 19
Hitachi Chemical Enters into Licensing Agreement with Progenitor Cell Therapy 20
AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 21
SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 21
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 22
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 23
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 24
NeoStem Enters Into Licensing Agreement With Tianjin Nankai Hospital 25
Equity Offering 26
Caladrius Biosciences to Raise USD21 Million in Private Placement of Shares 26
Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 28
Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 29
Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 29
NeoStem Raises USD29 Million in Public Offering of Shares 30
NeoStem to Raise USD30 Million in Private Placement of Shares 32
NeoStem Completes Public Offering Of Shares For US$40.25 Million 33
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 34
NeoStem Completes Public Offering Of Shares For US$11.5 Million 35
NeoStem Completes Private Placement Of Common Stock For US$3 Million 36
NeoStem Completes Public Offering Of Units For US$6.8 Million 37
NeoStem Completes An Underwritten Public Offering Of Units For US$16.5 Million 38
Acquisition 40
Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 40
NeoStem Completes Acquisition Of California Stem Cell 41
NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For US$12 Million 42
NeoStem Completes Acquisition Of Amorcyte 44
NeoStem Completes Acquisition Of Progenitor Cell Therapy 45
Caladrius Biosciences Inc - Key Competitors 47
Key Employees 48
Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50
List of Tables
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Caladrius Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Caladrius Biosciences Inc, Medical Devices Deals, 2011 to YTD 2017 11
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Amorcyte Raises US$0.5 Million In Venture Financing 14
Kiadis Pharma Enters into Agreement with PCT 14
Caladrius Biosciences Enters into Development Agreement with Sanford Research 15
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 16
NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 17
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 18
Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 19
Hitachi Chemical Enters into Licensing Agreement with Progenitor Cell Therapy 20
AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 21
SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 21
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 22
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 23
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 24
NeoStem Enters Into Licensing Agreement With Tianjin Nankai Hospital 25
Caladrius Biosciences to Raise USD21 Million in Private Placement of Shares 26
Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 28
Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 29
Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 29
NeoStem Raises USD29 Million in Public Offering of Shares 30
NeoStem to Raise USD30 Million in Private Placement of Shares 32
NeoStem Completes Public Offering Of Shares For US$40.25 Million 33
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 34
NeoStem Completes Public Offering Of Shares For US$11.5 Million 35
NeoStem Completes Private Placement Of Common Stock For US$3 Million 36
NeoStem Completes Public Offering Of Units For US$6.8 Million 37
NeoStem Completes An Underwritten Public Offering Of Units For US$16.5 Million 38
Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 40
NeoStem Completes Acquisition Of California Stem Cell 41
NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For US$12 Million 42
NeoStem Completes Acquisition Of Amorcyte 44
NeoStem Completes Acquisition Of Progenitor Cell Therapy 45
Caladrius Biosciences Inc, Key Competitors 47
Caladrius Biosciences Inc, Key Employees 48
Caladrius Biosciences Inc, Other Locations 49
Caladrius Biosciences Inc, Subsidiaries 49
List of Figures
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Caladrius Biosciences Inc, Medical Devices Deals, 2011 to YTD 2017 11
